---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010933"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:10:06.298396+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences FY2022 revenue up 47% to $9.96M; net loss per share improves to $25.65 from $27.56

## Summary
- Total revenues $9.956M, up 47% YoY; Q4 revenue $1.0M, down 54% YoY.
- Operating expenses $28.771M, down 32% YoY; cash used in operations $13.977M, down 46%.
- Net loss attributable to common stockholders $15.376M ($25.65/share) vs $14.660M ($27.56/share) in 2021.
- GoodWheat pasta launched in Q2 2022, reached 1,200+ stores within 7 months; AHA Heart-Check certified.
- CEO Stan Jacot appointed in Q1 2022; Project Greenfield 3-year plan for profitability.

## SEC filing metadata
- accession: 0000950170-23-010933
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/0000950170-23-010933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/rkda-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010933
- JSON: https://secwatch.observer/filing/0000950170-23-010933.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010933.txt

## Key facts
- Earnings Releases
  Arcadia Biosciences, Inc. reported financial results for fourth quarter and year ended December 31, 2022.
  - Period: fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023010933/0000950170-23-010933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.